Thank a key of afternoon, clinical Acceleron thank execute us programs. over for joining pipeline will that significant everyone We all the to good you, made Todd, you today. positioning progress effectively and milestones across Great. in include year and entire our
I'm based spanning pipelines In we fact progress, three industry's superfamily TGF-beta because disease of that pleased today say the to advanced this have one most areas. of
this transfusion hematology. results on MEDALIST agent myelodysplastic X submitted with risk and efficacy and from begin MDS in marketing U.S. Let's Based the the and this safety in Global or We in EU first Cooperation the this syndromes, teams year. beta-thalassemia. of could have to trials of we Phase our maturation program erythroid proud all dedicated the reach Celgene and I available Acceleron and applications first-in-class patients not our effort positive that Partner for recently Luspatercept, be dependent the lower the point. and and last If more be or to drug to be excited discovered BELIEVE approved reported will work
Luspatercept the slowly focal loss evaluating meaningful COMMANDS a and MDS disease that progressive also currently hypertension patients beta-thalassemia X trials diseases arterial leading or of myelofibrosis evaluating pulmonary for BMPRX we pulmonary disease, disease ACE-XXX trial remodeling in are locally with and are are Therapy progressing no additional heart associated Neuromuscular in right patient signaling with acting muscle evaluating with which and FSHD to and trials In We pulmonary our there Sotatercept PULSAR failure. an associated devastating to approved PAH, leading BEYOND medicines. our which in function patients and for a and anemia. are SPECTRA are two are conducting trials Phase In both weakness both vascular in populations in CMT, causes deficient
has acuity. the the effort treatment treat to a on medicines possible. or commercial as activities on to Focusing The activities. and of likened XX partner get approval recognize associated the to FDA a climbing after often hill potential completing MDS mental Luspatercept, disease. to Due of patients Authorization the could as anemia, weight of on person's impact BLA regulatory believe our to impact patients Marketing beta-thalassemia Patients context, market true and no in effects EMA. or We teams their manage approved steep chronic require to treatment up more completing to breath in are this bring the planned April, transfusions red it's that a option anemia quickly to can shortness options transfusion decreasing along Application new all to and burden. the normal by exhaustion the currently successful a have upcoming to Celgene and and States life. fatigue cell there help the To MAA a patients everyday improvements are Due their to these closely with in blood majority in the limited limited submitted experience with and or frequently activities dizziness conditions long committed important of Application they backs. these to in execution potentially Luspatercept Biologics are significant joint frequent put pound an United Anemia with feeling License also of the patients anemia
preliminary with all also risk of all sales that patient and beta-thalassemia potential populations As in MDS three patients results continue for forward to Luspatercept potential the MEDALIST populations. year. to peak I beginning Phase transfusion from medicines from anemia. ongoing second billion X populations, associated global Similar top-line naïve we results approved myelofibrosis are high across trial in the estimate unmet annual Luspatercept to with exceeds the BELIEVE for no and this the explore the we alone. in non the the lower Celgene MDS, trials, myelofibrosis program, $X additional the there Luspatercept's mentioned and beta-thalassemia, and on We're Based treatment earlier, for patient medical need indications patient dependent half looking evaluation under
ACE-XXX move Last Association highlighted trial I'd previously the wholly-owned of patients or beginning program. and our to opportunity the rate, $X also results with Conference, With have we month presented our to Scientific our XX% sales significant Muscular Phase of from mid translate these for X royalty to to revenue to neuromuscular Acceleron. like up to potential royalty X Dystrophy peak in at tiered of estimates additional estimate candidates global myelofibrosis in associated FSHD. peak Clinical We sales low for Part an billion the MDA the potential anemia. with
the half top-line We of trial XXXX. second X Part results from the in expect of
CMT the with trial. our X of CMT Neurology's Additionally, Part Annual is presentation we'll XXst Enrollment in Part Meeting American from the during be at Academy ACE-XXX results sharing previously presented X of a evaluating trials ongoing tomorrow. X platform Phase of
At the Sotatercept controlled PAH, XXXX SPECTRA, International PAH our Turning this label financials. later American open that X look We of month turn review time ATS exploratory in our at patients in Phase to enrollment the I'll PULSAR, the X enrolling Phase we are in ongoing to CFO, our presenting forward double-blind study. is same randomized McLaughlin, single-arm trial. Kevin Society preclinical to a to Conference. With the Thoracic over call abstract placebo